Cetera Investment Advisers Takes $311,000 Position in Grail, Inc. (NASDAQ:GRAL)

Cetera Investment Advisers bought a new stake in Grail, Inc. (NASDAQ:GRAL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 17,414 shares of the company’s stock, valued at approximately $311,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GRAL. Crcm LP acquired a new stake in shares of Grail in the fourth quarter valued at $65,061,000. Primecap Management Co. CA acquired a new stake in Grail in the fourth quarter worth about $37,118,000. Baker BROS. Advisors LP acquired a new stake in Grail in the fourth quarter worth about $29,098,000. Vanguard Group Inc. acquired a new stake in Grail in the fourth quarter worth about $25,902,000. Finally, AQR Capital Management LLC acquired a new stake in Grail in the fourth quarter worth about $14,828,000.

Grail Stock Down 8.3%

Shares of GRAL stock opened at $37.70 on Friday. The stock has a 50-day moving average price of $32.06 and a 200 day moving average price of $28.32. The firm has a market cap of $1.36 billion and a price-to-earnings ratio of -0.62. Grail, Inc. has a 12 month low of $12.33 and a 12 month high of $63.99.

Grail (NASDAQ:GRAL) last issued its earnings results on Tuesday, May 13th. The company reported ($3.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.03) by $0.93. The company had revenue of $31.84 million for the quarter, compared to the consensus estimate of $35.80 million. Sell-side analysts predict that Grail, Inc. will post -15.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Grail news, CFO Aaron Freidin sold 41,150 shares of the firm’s stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $33.93, for a total transaction of $1,396,219.50. Following the transaction, the chief financial officer now owns 294,020 shares in the company, valued at approximately $9,976,098.60. This trade represents a 12.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, President Joshua J. Ofman sold 2,109 shares of the firm’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $31.20, for a total value of $65,800.80. Following the transaction, the president now owns 559,673 shares in the company, valued at approximately $17,461,797.60. This trade represents a 0.38% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 194,948 shares of company stock worth $6,583,130. Insiders own 1.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Morgan Stanley lifted their price objective on Grail from $16.00 to $20.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 18th. Canaccord Genuity Group lifted their price objective on Grail from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Wednesday, May 14th.

About Grail

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.